ES
MARKETS / NASDAQ / IMCR
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Immunocore Holdings PLC IMCR

5 fiscal years on record · GBP · FY2022 reported
SEC FILINGS ONLY
Revenue · FY2022
£143.7M
▲ 442.0% vs FY2021
EPS · FY22
£-0.90
Dividend / sh · FY22
—
Payout · FY22
-0%
ROE · FY22
—
Net margin · FY22
-28.7%
Dividend coverage
-279.0×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
GBP 143.7M
Revenue, FY2022 · full 5-year series below
Revenue Net income
0.040.080.120.160.1-0.0201820212022
0.040.080.120.160.1-0.0201820212022

The company lost 29 cents on every revenue dollar this year.

Per share
GBP -0.90
Diluted EPS, FY2022
EPS Dividend
0.40.81.2-0.90201820212022
0.40.81.2-0.90201820212022

The dividend was paid in a year without profit.

Profitability
—
Return on equity, FY2022
ROE
0.250.50.751201820212022
0.250.50.751201820212022
Operating margin-27.6%
Net margin-28.7%
Return on assets-11.2%

Returned to shareholders
—
returned in FY2022 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit-0.0%
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+77.6%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
—
Shares outstanding, FY2022
0.000.00201820212022
0.000.00201820212022
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
GBP 435.5M
total assets, end of FY2022
Total assetsGBP 435.5M
CashGBP 332.5M
Gross debtGBP 39.5M
Net debtGBP -293.0M
Current ratio4.72×

History
5 fiscal years
Every figure from documents filed with the SEC · GBP
Metric
2022
2021
2020
2019
2018
Revenue £B
0.1
0.0
0.0
0.0
0.0
Operating income £B
−0.0
−0.1
−0.1
−0.1
−0.1
EBITDA £B
·
·
·
·
·
Income tax £B
−0.0
−0.0
−0.0
−0.0
−0.0
Net income £B
−0.0
−0.1
−0.1
−0.1
−0.1
EPS, diluted £
−0.90
−3.10
−2.79
−4.66
·
Dividend / sh £
·
·
0.01
·
·
Payout %
−0
−0
−0
−0
·
ROE %
·
·
·
·
·
Shares out B
·
0.00
0.00
0.00
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
12 of 12
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed